Geode Capital Management
CURX

Geode Capital Management’s Curanex Pharmaceuticals CURX Stock Holding History

Geode Capital Management’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2K Sell
1,914
-3,643
-66% -$26.5K ﹤0.01% 4421
2026
Q1 		$56.8K Buy
5,557
+4,623
+495% +$34.7K ﹤0.01% 4284
2025
Q4 		$6.17K Hold
934
– – ﹤0.01% 4451
2025
Q3 		$13.4K Buy
+934
New +$84.5K ﹤0.01% 4439

Other funds holding CURX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Geode Capital Management's CURX Position: Q2 2026 in Review

Geode Capital Management reduced its Curanex Pharmaceuticals (CURX) stake by 66% in Q2 2026, selling an estimated $26.5K and leaving 1,914 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4421.

Geode Capital Management first reported a position in CURX in Q3 2025 and has held it in 4 quarters since. The position peaked at $56.8K in Q1 2026. 11 funds tracked by Wall St. Rank hold CURX as of Q2 2026.

  • Geode Capital Management held 1,914 shares of Curanex Pharmaceuticals worth $10.2K as of Q2 2026.
  • Geode Capital Management sold 3,643 Curanex Pharmaceuticals shares in Q2 2026, an estimated $26.5K.
  • Curanex Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4421 holding.
  • Geode Capital Management first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Geode Capital Management's Curanex Pharmaceuticals position peaked at $56.8K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.